Home HEALTH Astex Pharmaceuticals, Inc (NASDAQ:ASTX)’s lead programs

Astex Pharmaceuticals, Inc (NASDAQ:ASTX)’s lead programs

0
0

Friday’s trading

In Friday’s trading session, Astex Pharmaceuticals, Inc (NASDAQ:ASTX) dropped by 0.47%. The shares opened at a price of $8.48 which climbed to an intraday high of $8.51 and dropped to a close of $8.47. Approximately 5.35 million shares were traded on Friday and the average volume of shares traded over 30 days was 5.02 million. The 52-week low of the shares is $2.14 and the 52-week high is $9.39. The company has a market capitalization of $8.0.54 million.

About the company

The pharmaceutical company, Astex Pharmaceuticals, Inc (NASDAQ:ASTX) was previously SuperGen, Inc and was incorporated in 1991 March 1991. It is mainly involved in discovering and developing small-molecule therapeutics and focuses on hematology and oncology. It is developing a variety of medicines and will partner with other pharmaceutical companies.

It is also involved in the application of fragment based drug-discovery and development of small molecule therapeutics. With the use of Pyramid, its fragment based drug-discovery platform, Astex Therapeutics Limited, a 100%-owned subsidiary, has created a pipeline of molecularly targeted drugs for big pharma-partners and internal-development that are at varying stages of pre clinical, clinical and early-discovery development. On 20 July 2011, the company completed the Astex Therapeutics Limited acquisition.

The lead programs

Astex Pharmaceuticals, Inc (NASDAQ:ASTX’s 2 lead internal programs are a 2nd generation hypomethylating-agent and SGI-110, and a HSP 90 inhibitor- AT13387. Amuvatinib is the 3rd product in its clinical-pipeline. This is a multi-targeted kinase inhibitor and a Deoxyribonucleic acid repair-suppressor. It has also partnered in ongoing clinical trials for CDK inhibitor- AT7519, an aurora/JAK2 inhibitor- AT9283,

Dacogen Hypomethylator

Dacogen is a DNA-hypomethylating agent that has received approval in specific markets. It is used to treat patients suffering from with myelodysplastic syndromes including previously-treated as well as untreated, de novo and secondary-MDS of all French-American-British subtypes and Intermediate-1/ Intermediate-2 and High-Risk International Prognostic Scoring-System groups.